Comparative in vitro activity of garenoxacin against Chlamydia spp.
The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.
Donati
M
M
Sezione di Microbiologia, DMCSS, University of Bologna, Policlinico S.Orsola-Malpighi, via Massarenti 9, 40138, Bologna, Italy.
Pollini
G M
GM
Sparacino
M
M
Fortugno
M T
MT
Laghi
E
E
Cevenini
R
R
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000188:drug therapy / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D016993:Chlamydophila pneumoniae / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D002691:Chlamydophila psittaci / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D024841:Fluoroquinolones; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use; D013754:Tetracyclines
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D007211:Indoles; D018942:Macrolides; D015363:Quinolones; D013754:Tetracyclines; C419689:garenoxacin